The nuclear bodies inside out: PML conquers the cytoplasm

Current Opinion in Cell Biology

Volumn 23, Issue 3, 2011, Pages 360-366

  Carracedo, Arkaitz ^a   Ito, Keisuke ^b   Pandolfi, Pier Paolo ^b  

^a CIC BIOGUNE   (Spain)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN;

CELL FUNCTION; CYTOPLASM; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW;

ANIMALS; CELL NUCLEUS; CYTOPLASM; HUMANS; INTRANUCLEAR INCLUSION BODIES; LEUKEMIA, PROMYELOCYTIC, ACUTE; TUMOR SUPPRESSOR PROTEINS;

EID: 79957798908     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2011.03.011     Document Type: Review

References (62)

1. Longo L., Donti E., Mencarelli A., Avanzi G., Pegoraro L., Alimena G., Tabilio A., Venti G., Grignani F., Pelicci P.G. Mapping of chromosome 17 breakpoints in acute myeloid leukemias. Oncogene 1990, 5:1557-1563.
2. Pandolfi P.P., Grignani F., Alcalay M., Mencarelli A., Biondi A., LoCoco F., Pelicci P.G. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991, 6:1285-1292.
3. de The H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:675-684.
4. Kakizuka A., Miller W.H., Umesono K., Warrell R.P., Frankel S.R., Murty V.V., Dmitrovsky E., Evans R.M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991, 66:663-674.
5. Goddard A.D., Borrow J., Freemont P.S., Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991, 254:1371-1374.
6. Koken M.H., Linares-Cruz G., Quignon F., Viron A., Chelbi-Alix M.K., Sobczak-Thepot J., Juhlin L., Degos L., Calvo F., de The H. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995, 10:1315-1324.
7. Liu J.H., Mu Z.M., Chang K.S. PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. J Exp Med 1995, 181:1965-1973.
8. Gurrieri C., Capodieci P., Bernardi R., Scaglioni P.P., Nafa K., Rush L.J., Verbel D.A., Cordon-Cardo C., Pandolfi P.P. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004, 96:269-279.
9. Huang M.E. Treatment of acute promyelocytic leukemia with all-trans retinoic acid. Zhonghua Yi Xue Za Zhi 1988, 68:131-133. 110.
10. Raelson J.V., Nervi C., Rosenauer A., Benedetti L., Monczak Y., Pearson M., Pelicci P.G., Miller W.H. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996, 88:2826-2832.
11. Sun H.D., Ma L., Hu X.C., Zhang T.D. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 1992, 12.
12. Zhang P., Wang S.Y., Hu L.H., Shi F.D., Qiu F.Q., Hong G.J., Han X.Y., Yang H.F., Sun Y.Z., Liu Y.P., et al. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996, 2.
13. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348.
14. Chen G.Q., Zhu J., Shi X.G., Ni J.H., Zhong H.J., Si G.Y., Jin X.L., Tang W., Li X.S., Xong S.M., et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996, 88:1052-1061.
15. Andre C., Guillemin M.C., Zhu J., Koken M.H., Quignon F., Herve L., Chelbi-Alix M.K., Dhumeaux D., Wang Z.Y., Degos L., et al. The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 1996, 229:253-260.
16. Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N., Jaffray E.G., Palvimo J.J., Hay R.T. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008, 10:538-546.
17. Lallemand-Breitenbach V., Jeanne M., Benhenda S., Nasr R., Lei M., Peres L., Zhou J., Zhu J., Raught B., de The H. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008, 10:547-555.
18. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., Liang W.X., Song A.X., Lallemand-Breitenbach V., Jeanne M., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
19. Grisolano J.L., Wesselschmidt R.L., Pelicci P.G., Ley T.J. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 1997, 89:376-387.
20. He L.Z., Tribioli C., Rivi R., Peruzzi D., Pelicci P.G., Soares V., Cattoretti G., Pandolfi P.P. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A 1997, 94:5302-5307.
21. Brown D., Kogan S., Lagasse E., Weissman I., Alcalay M., Pelicci P.G., Atwater S., Bishop J.M. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997, 94:2551-2556.
22. Lallemand-Breitenbach V., Guillemin M.C., Janin A., Daniel M.T., Degos L., Kogan S.C., Bishop J.M., de The H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999, 189:1043-1052.
23. Rego E.M., He L.Z., Warrell R.P., Wang Z.G., Pandolfi P.P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A 2000, 97:10173-10178.
24. Zhong S., Hu P., Ye T.Z., Stan R., Ellis N.A., Pandolfi P.P. A role for PML and the nuclear body in genomic stability. Oncogene 1999, 18:7941-7947.
25. Shen T.H., Lin H.K., Scaglioni P.P., Yung T.M., Pandolfi P.P. The mechanisms of PML-nuclear body formation. Mol Cell 2006, 24:331-339.
26. Lang M., Jegou T., Chung I., Richter K., Munch S., Udvarhelyi A., Cremer C., Hemmerich P., Engelhardt J., Hell S.W., et al. Three-dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci 2010, 123:392-400.
27. Fagioli M., Alcalay M., Pandolfi P.P., Venturini L., Mencarelli A., Simeone A., Acampora D., Grignani F., Pelicci P.G. Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 1992, 7:1083-1091.
28. Condemine W., Takahashi Y., Zhu J., Puvion-Dutilleul F., Guegan S., Janin A., de The H. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res 2006, 66:6192-6198.
29. Weidtkamp-Peters S., Lenser T., Negorev D., Gerstner N., Hofmann T.G., Schwanitz G., Hoischen C., Maul G., Dittrich P., Hemmerich P. Dynamics of component exchange at PML nuclear bodies. J Cell Sci 2008, 121:2731-2743.
30. Wang J., Shiels C., Sasieni P., Wu P.J., Islam S.A., Freemont P.S., Sheer D. Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions. J Cell Biol 2004, 164:515-526.
31. Shiels C., Islam S.A., Vatcheva R., Sasieni P., Sternberg M.J., Freemont P.S., Sheer D. PML bodies associate specifically with the MHC gene cluster in interphase nuclei. J Cell Sci 2001, 114:3705-3716.
32. Kumar P.P., Bischof O., Purbey P.K., Notani D., Urlaub H., Dejean A., Galande S. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus. Nat Cell Biol 2007, 9:45-56.
33. Sun Y., Durrin L.K., Krontiris T.G. Specific interaction of PML bodies with the TP53 locus in Jurkat interphase nuclei. Genomics 2003, 82:250-252.
34. Kiesslich A., von Mikecz A., Hemmerich P. Cell cycle-dependent association of PML bodies with sites of active transcription in nuclei of mammalian cells. J Struct Biol 2002, 140:167-179.
35. Seeler J.S., Marchio A., Sitterlin D., Transy C., Dejean A. Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc Natl Acad Sci U S A 1998, 95:7316-7321.
36. Wu W.S., Vallian S., Seto E., Yang W.M., Edmondson D., Roth S., Chang K.S. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 2001, 21:2259-2268.
37. Luciani J.J., Depetris D., Usson Y., Metzler-Guillemain C., Mignon-Ravix C., Mitchell M.J., Megarbane A., Sarda P., Sirma H., Moncla A., et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase. J Cell Sci 2006, 119:2518-2531.
38. Zhang R., Poustovoitov M.V., Ye X., Santos H.A., Chen W., Daganzo S.M., Erzberger J.P., Serebriiskii I.G., Canutescu A.A., Dunbrack R.L., et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 2005, 8:19-30.
39. Ye X., Zerlanko B., Zhang R., Somaiah N., Lipinski M., Salomoni P., Adams P.D. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007, 27:2452-2465.
40. Vernier M., Bourdeau V., Gaumont-Leclerc M.F., Moiseeva O., Begin V., Saad F., Mes-Masson A.M., Ferbeyre G. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev 2011, 25:41-50.
41. Regad T., Bellodi C., Nicotera P., Salomoni P. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat Neurosci 2009, 12:132-140.
42. Trotman L.C., Alimonti A., Scaglioni P.P., Koutcher J.A., Cordon-Cardo C., Pandolfi P.P. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006, 441:523-527.
43. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002, 4:1-10.
44. Lee Y.R., Yuan W.C., Ho H.C., Chen C.H., Shih H.M., Chen R.H. The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. EMBO J 2010, 29:1748-1761.
45. Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H., Pandolfi P.P. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 2004, 6:665-672.
46. Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., Teruya-Feldstein J., Pandolfi P.P. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008, 455:813-817.
47. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000, 406:207-210.
48. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002, 21:2383-2396.
49. Insinga A., Monestiroli S., Ronzoni S., Carbone R., Pearson M., Pruneri G., Viale G., Appella E., Pelicci P., Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 2004, 23:1144-1154.
50. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M.C., Rafii S., Pandolfi P.P. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006, 442:779-785.
51. Bernardi R., Papa A., Egia A., Coltella N., Teruya-Feldstein J., Signoretti S., Pandolfi P.P. Pml represses tumour progression through inhibition of mTOR. EMBO Mol Med 2011.
52. Lin H.K., Bergmann S., Pandolfi P.P. Cytoplasmic PML function in TGF-beta signalling. Nature 2004, 431:205-211.
53. Giorgi C., Ito K., Lin H.K., Santangelo C., Wieckowski M.R., Lebiedzinska M., Bononi A., Bonora M., Duszynski J., Bernardi R., et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 2010, 330:1247-1251.
54. Bernardi R., Pandolfi P.P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007, 8:1006-1016.
55. Seo S.R., Ferrand N., Faresse N., Prunier C., Abecassis L., Pessah M., Bourgeade M.F., Atfi A. Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling. Mol Cell 2006, 23:547-559.
56. Bellodi C., Kindle K., Bernassola F., Dinsdale D., Cossarizza A., Melino G., Heery D., Salomoni P. Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha. J Biol Chem 2006, 281:14465-14473.
57. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., Pandolfi P.P. PML is essential for multiple apoptotic pathways. Nat Genet 1998, 20:266-272.
58. Zheng P., Guo Y., Niu Q., Levy D.E., Dyck J.A., Lu S., Sheiman L.A., Liu Y. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998, 396:373-376.
59. Gurrieri C., Nafa K., Merghoub T., Bernardi R., Capodieci P., Biondi A., Nimer S., Douer D., Cordon-Cardo C., Gallagher R., et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 2004, 103:2358-2362.
60. Jul-Larsen A., Grudic A., Bjerkvig R., Boe S.O. Subcellular distribution of nuclear import-defective isoforms of the promyelocytic leukemia protein. BMC Mol Biol 2010, 11:89.
61. Hayakawa F., Abe A., Kitabayashi I., Pandolfi P.P., Naoe T. Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J Biol Chem 2008, 283:24420-24425.
62. Reineke E.L., Lam M., Liu Q., Liu Y., Stanya K.J., Chang K.S., Means A.R., Kao H.Y. Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol 2008, 28:997-1006.